Irska - engleski - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - adrenergic and dopaminergic agents

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

niche generics ltd - bumetanide - oral tablet - 1mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide tablets, usp are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. bumetanide tablets, usp are contraindicated in anuria. although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte deple

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bryant ranch prepack - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide tablets, usp are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide tablets, usp following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. bumetanide is contraindicated in anuria. although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected. bumetanide is contraindicated in patients hypersensitive to this drug.

Irska - engleski - HPRA (Health Products Regulatory Authority)

leo laboratories limited - bumetanide - solution for injection - 0.5 mg/ml

Irska - engleski - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - solution for infusion - 5 mg/ml

Irska - engleski - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - solution for infusion - 5 mg/ml

Singapur - engleski - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - dapagliflozin propanediol 6.15mg eqv dapagliflozin - tablet, film coated - 5mg - dapagliflozin propanediol 6.15mg eqv dapagliflozin 5mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - bumetanide - oral tablet - 5mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - bumetanide - oral tablet - 5mg